AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook

  • Revenue of $32.6 million – up 22.9% as reported, 26.5% constant currency
  • U.S. sales of $25.7 million – up 29.3%
  • International sales of $6.8 million – up 3.5% as reported, 17.9% constant currency

WEST CHESTER, Ohio--- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, today announced second quarter 2015 financial results.

“We are pleased by our results this quarter which reflect continued stability in our business and the solid foundation AtriCure is building for future growth,” said Mike Carrel, President and Chief Executive Officer of AtriCure. “With our long term investments in clinical trials, innovation, and physician training and education, we look forward to continuing to advance the treatment of atrial fibrillation.”

Merit Medical Reports Record Revenues for the Quarter and Six Months Ended June 30, 2015

Non-GAAP Net Income Up 70% for 2Q, Revenues Up 7.2% for 2Q
Revenues Up 10% for 2Q and YTD When Adjusted for Constant Currency

Non-GAAP Gross Margin Up 80 Basis Points Over 2Q 2014 and Up 124 Basis Points Over 1Q 2015
Expense Discipline Continues, Tijuana, Mexico Facility Commences Production

SOUTH JORDAN, Utah, July 23, 2015  -- Merit Medical Systems, Inc. (MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and endoscopy, today announced record revenues of $138.1 million for the quarter ended June 30, 2015, an increase of 7% over revenues of $128.9 million for the quarter ended June 30, 2014.  Revenues for the six-month period ended June 30, 2015 were a record $267.7 million, compared to $248.1 million for the corresponding period in 2014, an increase of 8%.   The growth of revenues in constant currency would have been 10% for both the quarter and the six months ended June 30, 2015.

Intuitive Surgical Announces Second Quarter Earnings

SUNNYVALE, Calif., July 21, 2015  -- Intuitive Surgical, Inc. (ISRG), the industry leader in robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2015.

Q2 Highlights

  • Worldwide da Vinci procedures grew approximately 14% over the second quarter of 2014, up 8% sequentially over the first quarter of 2015, driven primarily by growth in U.S. general surgery procedures and broad-based procedure growth in Asia and other international markets.
  • The Company shipped 118 da Vinci Surgical Systems, compared to 96 in the second quarter of 2014 and 99 in the first quarter of 2015.
  • Non-GAAP* revenue of $586 million for the quarter grew approximately 16% compared with $507 million for the second quarter of 2014.

Vascular Solutions Reports Second Quarter Results

  • Revenue increased 22% to $37.6 million, exceeding the top end of guidance
  • Adjusted EPS increased 38% to $0.29, exceeding the top end of guidance; GAAP EPS of $0.21
  • Raising 2015 revenue guidance to $145-$147 million, representing an increase of 16% at the midpoint
  • Raising 2015 adjusted EPS guidance to $1.00-$1.04

MINNEAPOLIS, July 21, 2015  -- Vascular Solutions, Inc. (VASC) today reported financial results for the second quarter ended June 30, 2015.

Worldwide revenue increased 22% from the second quarter of 2014 to $37.6 million, which exceeded the company’s revenue guidance range of $35.5 million to $36.5 million and set a new quarterly revenue record. U.S. revenue increased 14% to $28.7 million, while international revenue increased 60% to $8.9 million.

Thoratec Announces Preliminary Second Quarter Revenue

PLEASANTON, Calif., July 22, 2015 -- Thoratec Corporation (THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced preliminary unaudited revenue in the range of $128 million to $129 million for the second quarter of 2015.

"Our strong second quarter performance resulted from a broad increase in utilization of our products globally, driven in particular by favorable trends in our North American HeartMate franchise," said D. Keith Grossman, President and Chief Executive Officer.  "We continued to make progress with our commercial initiatives and clinical trials, and we are pleased to see a positive impact from these efforts," he added.

Videos / Webinars

View all videos

Stockjunction Members

View All Members